Despite executive orders by the Biden administration aimed to improve competition in the pharmaceutical industry, pay-for-delay deals and other antitrust issues continue to be reported. On this episode of Managed Care Cast, we speak on the history and prevalence of these anticompetitive tactics and steps to limit these deals.
In the past year, executive orders by the Biden administration have aimed to improve competition in the pharmaceutical industry by addressing pay-for-delay deals that work to prevent generics from entering the market. Although a step in the right direction, anticompetitive deals continue to be reported as the Federal Trade Commission weighs how to properly penalize involved drug companies.
On this episode of Managed Care Cast, we speak with Michael Abrams, managing partner at Numerof & Associates, on persistent barriers to entry for generics entering the pharmaceutical market, the impact of antitrust laws issued by the Biden administration, and further steps that are warranted to address anticompetitive tactics.